Abstract

Protein-protein interactions (PPIs) are known to play an essential role between the neuronal calcium sensor 1 (NCS-l) and the guanine exchange factor Ric8a to regulate synapse function, emerging as a draggable interface for synaptopathies such as the fragile X syndrome (FXS). Recently, the phenothiazine FD44 has been identified as an inhibitor of this PPI, decreasing the abnormally high synapse number and enhancing associative learning in a FXS animal model.Here, we have integrated advanced experimental and computational studies to obtain important structural insights into Drosophila NCS-1/FD44 recognition to understand the basis of its affinity and specificity and generate improved PPI regulators. This has allowed the identification of a new small drug-liKe molecule, IGS-1.76, which efficiently inhibits the human NCS-l/Ric8a complex with improved binding potency. The crystal structure of the Drosophila NCS-l/IGS-1.76 complex demonstrates that the new inhibitor, although chemically different from FD44, shares the same mechanism of action and constitutes a new hit candidate for FXS.